D.E. Shaw & Co
CYCN icon

D.E. Shaw & Co’s Cyclerion Therapeutics CYCN Stock Holding History

D.E. Shaw & Co’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,112
Closed -$136K – 5409
2022
Q1 		$136K Sell
6,112
-718
-11% -$17.3K ﹤0.01% 4951
2021
Q4 		$235K Sell
6,830
-6,798
-50% -$321K ﹤0.01% 4800
2021
Q3 		$837K Sell
13,628
-5,135
-27% -$336K ﹤0.01% 3748
2021
Q2 		$1.46M Buy
18,763
+15,339
+448% +$960K ﹤0.01% 3238
2021
Q1 		$191K Sell
3,424
-5,640
-62% -$424K ﹤0.01% 3861
2020
Q4 		$555K Buy
9,064
+4,187
+86% +$285K ﹤0.01% 3338
2020
Q3 		$593K Sell
4,877
-2,246
-32% -$257K ﹤0.01% 3143
2020
Q2 		$842K Buy
7,123
+2,768
+64% +$231K ﹤0.01% 3044
2020
Q1 		$231K Sell
4,355
-9,284
-68% -$662K ﹤0.01% 3586
2019
Q4 		$742K Buy
13,639
+8,142
+148% +$760K ﹤0.01% 3184
2019
Q3 		$1.33M Buy
5,497
+15
+0.3% +$3.24K ﹤0.01% 2657
2019
Q2 		$1.25M Buy
+5,482
New +$1.55M ﹤0.01% 2539

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

D.E. Shaw & Co's CYCN Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Cyclerion Therapeutics (CYCN) in Q2 2022, closing a stake of 6,112 shares — an estimated $136K sold.

D.E. Shaw & Co first reported a position in CYCN in Q2 2019 and held it in 12 quarters. The position peaked at $1.46M in Q2 2021. 41 funds tracked by Wall St. Rank hold CYCN as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Cyclerion Therapeutics position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 6,112 Cyclerion Therapeutics shares in Q2 2022, an estimated $136K.
  • D.E. Shaw & Co first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 12 quarters.
  • D.E. Shaw & Co's Cyclerion Therapeutics position peaked at $1.46M in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.